ArticleBritish journal of pharmacology2015
Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats.
Article in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the ATFrontiers in pharmacology · 2024Article
- The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective.Advances in experimental medicine and biology · 2024Review
- Leptin, the brain and energy homeostasis: From an apparently simple to a highly complex neuronal system.Reviews in endocrine & metabolic disorders · 2022Review
- The AT1 Receptor Blocker Telmisartan Reduces Intestinal Mucus Thickness in Obese Mice.Frontiers in pharmacology · 2022Article
- Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Impaired Leptin Signalling in Obesity: Is Leptin a New Thermolipokine?International journal of molecular sciences · 2021Review
- Interaction of Orexin A and Vasopressin in the Brain Plays a Role in Blood Pressure Regulation in WKY and SHR Rats.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats.Metabolic brain disease · 2020Article
- The antiobese effect of AT1 receptor blockade is augmented in mice lacking Mas.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Telmisartan prevents diet-induced obesity and preserves leptin transport across the blood-brain barrier in high-fat diet-fed mice.Pflugers Archiv : European journal of physiology · 2018Article
- Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.The Journal of endocrinology · 2018Article
- Development of obesity can be prevented in rats by chronic icv infusions of AngII but less by Ang(1-7).Pflugers Archiv : European journal of physiology · 2018Article
- The intricacies of the renin-angiotensin-system in metabolic regulation.Physiology & behavior · 2017Review
- Glucagon increase after chronic ATNaunyn-Schmiedeberg's archives of pharmacology · 2017Article
- Angiotensin AT1A receptors on leptin receptor-expressing cells control resting metabolism.The Journal of clinical investigation · 2017Article
- The brain renin-angiotensin system plays a crucial role in regulating body weight in diet-induced obesity in rats.British journal of pharmacology · 2016Article
- Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.British journal of pharmacology · 2015Article
- Effect of Angiotensin(1-7) on Heart Function in an Experimental Rat Model of Obesity.Frontiers in physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAT1 receptor blockers (ARBs) represent an approach for treating metabolic syndrome due to their potency in reducing hypertension, body weight and onset of type 2 diabetes. The mechanism underlying ARB-induced weight loss is still unclear. EXPERIMENTAL APPROACH: Leptin resistance tests (LRTs) in diet-induced obese or lean rats were conducted to determine whether telmisartan (8 mg·kg(-1) ·day(-1) , 14 days) enhances leptin sensitivity. Phosphorylation of signal transducer and activator of transcription 3 (pSTAT3) staining was performed in hypothalami to determine leptin transport across the blood-brain barrier. KEY
resultsTelmisartin reduced weight gain, food intake and plasma leptin but blood pressure remained unchanged. The 24 h profiles of plasma leptin after saline injections were similar in controls and telmisartan-treated rats, but after leptin injections were higher in controls and slightly lower in telmisartan-treated animals. After telmisartan, energy intake during LRT was lower in leptin- than in saline-pretreated rats, but remained unchanged in controls, irrespectively of whether rats received saline or leptin. Leptin minimized the gain in body weight during LRT in telmisartan-treated rats as compared with saline-treated animals. pSTAT3 staining was reduced in cafeteria diet-fed rats as compared with chow-fed rats but this was normalized by telmisartan. Telmisartin reduced hypothalamic mRNA levels of the orexigenic peptides melanin-concentrating hormone and prepro-orexin. CONCLUSIONS AND IMPLICATIONS: Rats fed a cafeteria diet develop leptin resistance after 2 weeks. Leptin sensitivity was preserved by telmisartan treatment even in rats fed a cafeteria diet. This pleiotropic effect is not related to the hypotensive action of telmisartan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.